RLMD Earnings Date: Nov 12, 2026 (Estimated) — Relmada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RLMD's next earnings date?
Relmada Therapeutics, Inc. (RLMD) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14.
How did RLMD do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Relmada Therapeutics, Inc. posted EPS of -$0.11 versus the -$0.20 estimate, a beat of 45.0%. Revenue was $0. The stock's 1-day post-earnings move was -8.0%.
How much does RLMD stock move after earnings?
RLMD beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.5% (up or down) in the day after earnings.
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.20 | -0.11 | +45.00% | $0 | ✅ Beat | -8.01% | -11.55% | -17.50% |
| 2026-05-12 | Q1 2026 | -0.19 | -0.22 | -15.79% | $0 | ❌ Miss | +0.54% | -5.64% | -12.48% |
| 2026-03-19 | Q4 2025 | -0.14 | -0.27 | -92.86% | $0 | ❌ Miss | -2.88% | +4.48% | +17.92% |
| 2025-11-13 | Q3 2025 | -0.04 | -0.30 | -650.00% | $0 | ❌ Miss | +1.80% | +11.34% | +12.37% |
| 2025-03-27 | Q4 2024 | -0.70 | -0.62 | +11.43% | $0 | ✅ Beat | -0.44% | -7.42% | +19.83% |
| 2024-11-07 | Q3 2024 | -0.64 | -0.72 | -12.50% | $0 | ❌ Miss | +0.61% | -3.07% | -85.25% |
| 2024-08-07 | Q2 2024 | -0.83 | -0.59 | +28.92% | $0 | ✅ Beat | -29.01% | -20.68% | -25.93% |
| 2024-05-08 | Q1 2024 | -0.88 | -0.72 | +18.18% | $0 | ✅ Beat | -0.78% | -9.14% | -22.98% |
Showing last 8 quarters.